89 / 1609
• No significant differences in local control and
survival
• Overall complications and side effects
observed after 6 months significantly more
frequent (
p
< 0.01) in the higher dose rate
group
Haie e.a. Int. J. Radiat. Oncol. Biol. Phys. 29, 953-960, 1994
.
IGR phase III trial